Arca
Skip to content
Tools
Tools

Myotonic dystrophy

Drug research and approvals for myotonic dystrophy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 40 studies of myotonic dystrophy are recruiting on ClinicalTrials.gov, Health Canada has authorized 13 drug trials for it since 2013, and FDA has 0 approved and 11 open orphan designations naming it.

  • Recruiting worldwide: 40
  • Trials authorized in Canada: 13
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 40 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Phase 3 1

Phase 2 3

How its trials ended

100 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 12 whose ending is known, 50% met their primary endpoint, 8% missed it and 42% stopped early.

  • Ongoing4242%
  • Completed, result not reported3636%
  • Status unknown1010%
  • Met its primary endpoint66%
  • Stopped: other or unclear55%
  • Missed its primary endpoint11%

Trials authorized in Canada

The 10 newest of 13; search them all in Canada trials
Jan 14, 2026A phase 1, open-label trial to assess the safety and pharmacokinetics of multiple ascending doses of DT-818 in healthy volunteers and participants with…DT-818Design TherapeuticsOngoing
Aug 28, 2025A global phase 3 open-label extension study to assess the long-term safety, tolerability, and efficacy of intravenous aoc 1001 for the treatment of myotonic…Aoc 1001 (AV01MAB-MD01-DS001)Avidity BiosciencesOngoing
Jul 11, 2025A phase 1/phase 2 open-label single arm study with dose escalation (part a), and dose expansion (part b) parts to evaluate the safety, tolerability, and…SAR446268Sanofi-Aventis Canada IncOngoing
Jul 8, 2025An open-label extension study evaluating safety and pharmacokinetics in participants with myotonic dystrophy type 1 (freedom-ole)PGN-EDODM1PepGenOngoing
Jun 28, 2024A phase 3 randomized, double-blind, placebo-controlled, global study to evaluate the efficacy and safety of intravenous aoc 1001 for the treatment of myotonic…Aoc 1001 (AV01MAB-MD01-DS001)Avidity BiosciencesClosed
May 17, 2024A phase 2 randomized, double-blind, placebo-controlled, multiple-ascending dose study of pgn-EDODM1 in adult participants with myotonic dystrophy type 1…PGN-EDODM1PepGenOngoing
Apr 12, 2024A phase 1/2a dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-DM1 (SRP-1003) in subjects with type 1…SRP-1003 (ARO-DM1, ADS-019)Sarepta TherapeuticsOngoing
Mar 14, 2024A phase 1/2a double-blind, placebo-controlled, single- and multiple ascending dose study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics…ATX-01 (X82108)Arthex Biotech, S.L.Ongoing
Nov 2, 2023A phase 1/2, randomized, double-blind, placebo¿controlled single- and multiple¿dose escalation study evaluating the safety, tolerability, pharmacokinetics, and…VX-670Vertex PharmaceuticalsOngoing
Aug 18, 2023A phase 1 placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single-ascending doses of pgn-EDODM1 in adult…PGN-EDODM1PepGenClosed

FDA orphan designations

Approved first, then open designations, newest first
Oct 17, 2025An antibody-siRNA conjugate, comprised of a humanized…Treatment of myotonic dystrophy type 1 (DM1)ChainGen Biopharma Ltd.Designated
Jun 26, 2025MecaserminTreatment of myotonic dystrophy type 1Sarcomed ABDesignated
Sep 20, 2024A phosphorodiamidate morpholino oligomer consisting of 7…Treatment of Myotonic Dystrophy Type 1Vertex Pharmaceuticals IncorporatedDesignated
Jul 10, 2024A nonreplicating adeno-associated virus, serotype SAN011…Treatment of myotonic dystrophy type 1Sanofi US Services Inc.Designated
Nov 27, 2023Recombinant fusion protein (biologic) made by linking human…Treatment of myotonic dystrophy type 1Juvena Therapeutics, Inc.Designated
Sep 19, 2023Human transferrin 1 receptor (TfR1) targeting humanized IgG…Treatment of Myotonic Dystrophy Type IDyne Therapeutics, Inc.Designated
Aug 1, 2023A synthetic peptide-oligonucleotide conjugate in which a…Treatment of Myotonic Dystrophy type 1 (also known as Steinert disease)PepGen Inc.Designated
May 10, 2022A lyophilized modified oligonucleotide of 16 nucleotides…Treatment of myotonic dystrophy type 1 (DM1)Arthex Biotech S.L.Designated
Jul 21, 2021An antibody oligonucleotide conjugate (AOC), comprised of a…Treatment of Myotonic Dystrophy Type 1 (DM1)Avidity BiosciencesDesignated
Jun 19, 2017TideglusibTreatment of myotonic dystrophy type 1 (DM1)AMO Pharma Ltd.Designated
Dec 3, 2007MecaserminTreatment of myotonic dystrophyInsmed, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.